Biotech Values

[genisi]

End of the way for narlaprevir (SCH 900518), MK-7009 is the chosen one:

Merck had to choose among similar drugs in two research areas: hepatitis C and cancer. In December, Merck said its hepatitis C drug, MK-7009, also known as vaniprevir, would take priority over a similar drug from Schering.

http://www.nasdaq.com/aspx/stock-market-news-story.aspx?storyid=201003011141dowjonesdjonline000505&title=merck-touts-heart-infection-drugs-in-pipeline-update